DPYSL2 and colorectal carcinoma: In support of the previous findings that CRMP2 is significantly decreased in CRC patients with diabetic comorbidity, we documented that hyperglycemia inhibits CRMP2 expression and suppresses adipogenic machinery and adipocyte markers (Figure 6).